Pioneering Microalgae-Based Innovations in Drug Development and Biotechnology
Highlight of FEBICO during BioJapan 2024
FEBICO specializes in the commercialization of microalgae applications. Our state-of-the-art microalgae research facility supports a broad range of capabilities, including lead candidate discovery, cell culturing, regenerative medicine, and novel drug development. One of our primary focuses is on liver damage and liver fibrosis treatments.
Our lead drug candidate, FB1603, is a well-characterized extract from microalgae. It is currently in Phase 2 clinical trials in Taiwan, administered orally to patients who have undergone liver resection, with the aim of treating liver damage.
Our second lead compound, FB1807, is a pure compound currently in the preclinical stage. Independent human studies on the raw material of FB1807 have shown promising results, including the reversal of fibrosis in patients with hepatocellular carcinoma or chronic HBV within six months. Additionally, FB1807 has been found to induce apoptosis in TGF-beta activated hepatic stellate cells (HSC) specifically, without causing cytotoxicity in other cell types, such as fibroblasts, hepatoma cells, adenoma cells, and non-activated HSC.
FEBICO is also investing significant resources into the development of extracellular vesicles from microalgae. Our first application in this area is for exosome-based cosmetics, with an INCI application in progress. Our microalgae exosomes offer benefits such as skin whitening, anti-wrinkle effects, and tissue repair. These exosomes are available in various formulations, including serum, cream, and masks. Samples are available upon request.
Finally, we are leveraging the powerful antioxidant properties of microalgae in a specialized line of supplements designed to protect nerve cells and prevent tinnitus. This product line is endorsed by ENT doctors, and we are seeking global distribution partners.
The objective of attending BioAsia is to find partners for co-developing new drugs and advancing them to Phase III clinical trials.
Pioneering Microalgae-Based Innovations in Drug Development and Biotechnology | EU & USDA Chlorella, Spirulina & Dietary Supplements Manufacturer | Far East Bio-Tec Co., Ltd.
Located in Taiwan since 1976, Far East Bio-Tec Co., Ltd. has been a chlorella, spirulina and dietary supplements manufacturer. Their main products, include Organic Spirulina, Organic Chlorella, Spirulina Natural, Chlorella Natural and Nutritional Supplements, which are produced with advanced fermentation facilities to produce high-quality nattokinase and spore-forming probiotics.
With nearly 50 years of experience, FEBICO is committed to providing high-quality microalgae superfoods and health supplements to our global customers, along with exceptional service. Manufacturer of spirulina and chlorella (organic certified and natural) in Febico brand finish product, raw powder, bulk tablets, private labeling and OEM/ODM.
FEBICO has been offering customers Naturland / EU and USDA-NOP certified chlorella, spirulina and dietary supplements, both with advanced technology and 47 years of experience, FEBICO ensures each customer's demands are met.